The Centers for Medicare and Medicaid Services (CMS) is rolling out a program this summer that will provide more affordable ...

The Centers for Medicare & Medicaid Services has postponed its BALANCE pilot program for GLP‑1 obesity drug coverage until at least 2027 after insurers balked at costs and risks. In its place, CMS ...

Medicare delayed a plan to make insurance companies cover GLP-1 drugs Wegovy and Zepbound. Instead, Medicare will cover the ...

The RAPID pathway could cut the wait for Medicare coverage from over a year to about 2 months after FDA market authorization ...

The pathway is designed to reduce the delay between FDA authorization and Medicare coverage for certain Class II and Class ...

The agencies’ initiative is intended to speed up the processes involved in medical devices’ securing Medicare coverage once approved by the FDA.

CMS pauses weight-loss BALANCE model for Medicare Part D after insufficient plan sponsor participation, while Medicaid pilot continues.

The Centers for Medicare and Medicaid Services (CMS) and the U.S. Food and Drug Administration (FDA) announced on Thursday ...

The Centers for Medicare and Medicaid Services has introduced a new coverage pathway for Medicare beneficiaries to get ...

The Trump administration decided to put the pilot on hold until at least 2027.

The BALANCE program was intended to cover weight-loss drugs for Medicaid beneficiaries, but is delayed. A new solution with ...